Browse

Berkeley Haas Case Series

Case Information


Resilience at InterMune: A Journey Through the Valley of the Shadow of Death
Bahrami, Homa
Publication date: 6/10/2015, pages 1-29

This case is about California-based biotechnology company, InterMune, that despite many setbacks, ultimately succeeded in developing an orphan drug used to treat a deadly lung disease. In 2014, InterMune was acquired by Roche/Genentech for $8.3 billion, a significant premium over it's trading price. With resilience, InterMune’s CEO, Dan Welch, led through numerous strategic pivots, leadership changes, clinical trial disappointments, multiple divestitures, and ultimately the sale of the company. Specifically, Welch sharpened InterMune’s strategic focus on a few indications, evolved the Board and the leadership team, and orchestrated a grassroots initiative to re-invent InterMune’s core values and cultural pillars.
 


Educators may request a complimentary preview before purchasing. To find out more, please read about our publishing partnerships.

To request permission, please submit a Copyright Permission Request Form.